Impact of inhibitors and L2 antibodies upon the infectivity of diverse alpha and beta human papillomavirus types.

ABSTRACT: The licensed human papillomavirus (HPV) vaccines elicit type-restricted immunity but do not target cutaneous HPV types of the beta genus that are associated with non-melanoma skin cancer in immune-compromised patients, and it is unclear if these diverse types share a common mechanism of infection. Residues 11-88 of minor capsid protein L2 contain cross-protective epitopes, and vaccination with concatamers of this region derived from as many as eight alpha HPV (L2 α11-88x8) is being developed as an alternative prophylactic vaccine with potentially broader efficacy. There is also interest in developing broadly protective topical microbicides, such as carrageenan or heparin that block HPV receptor interactions, or small molecule inhibitors of infection. Here we have examined several inhibitor

SUBMITTER: Kwak K 

PROVIDER: S-EPMC4016295 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature